Life sciences and biotechnology are widely regarded as one of
the most promising frontier technologies for the coming decades.
Patent protection is at the core of the business for biotechnology
companies, and for them, it is also crucial to understand that
there exist strong differences amongst jurisdictions concerning
what is considered as patentable subject matter, what disclosure is
required, and what claim breath is allowed.
One distinctive feature in biotechnology is to define claims by
biological sequences (such as nucleotide sequences, amino acid
sequences). In China, however, whether these claims are supported
in view of examples provided in the description is a prominent
issue. A recent case from Supreme People's Court may shed some
lights on the Chinese examination inquiry. This short article
discussed the case, as well as Chinese practice.